New Approaches to Fight Serious Diseases.
VBL Therapeutics is an innovative, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases.
Our clinical pipeline is based on two distinct, proprietary, innovative platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, we have developed two programs based on these platforms – an oncology program and
an anti-inflammatory program.
Novel Technology, Promising Therapies.
Our innovative, proprietary VTS™ (Vascular Targeting System) platform technology enables systemic administration of gene therapy to either destroy or promote angiogenic blood vessels. VTS is both tissue- and condition-specific, allowing for targeted and limited gene expression in endothelial cells undergoing angiogenesis.
VBL's proprietary Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body’s inflammatory response. Lecinoxoids are structurally and functionally similar to naturally occurring anti-inflammatory molecules, but are modified to enhance stability and activity. We believe that Lecinoxoids hold significant promise in their ability to treat a broad range of chronic immune-based inflammatory diseases.
Making an Impact for Patients in the Clinic.
We are developing VB-111, the lead oncology product candidate from our VTS platform technology, for solid tumor indications, with current clinical trials in recurrent GBM, thyroid cancer and ovarian cancer.
Our first-in-class compound, VB-201 has completed Phase 2 clinical proof-of-concept studies for the treatment of psoriasis and inflammation in atherosclerosis. VB-201 is currently in a second Phase 2 study in psoriasis and an exploratory Phase 2 in ulcerative colitis.
Find out more about
VB-111 Clinical Development:
VB-201 Clinical Development: